Lexaria’s Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
New formulation delivers up to 2,708% more CBD into bloodstream* – Human clinical hypertension study HYPER-H21-1 also progressing
Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH™ 2.0” cannabidiol (“CBD”) formulations in its second 2021 applied research and development study program, HYPER-A21-2.